Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer

Affiliations

PMID: 32826069
DOI: 10.1016/j.surg.2020.06.038

Abstract

Background: Historically, germline testing of patients with pancreatic cancer was performed selectively in patients with a strong family history of cancer. Current guidelines recommend universal testing because some patients may have actionable germline pathogenic variants without family history.

Methods: We conducted a cost-effectiveness analysis using a decision-tree model to compare universal versus selective testing strategies for patients with pancreatic cancer. Costs, probabilities, and overall survival were estimated from the published literature and institutional data. One-way and probabilistic sensitivity analyses explored model uncertainty.

Results: Universal germline genetic testing had an incremental cost of $310 with an increase of 0.003 life-years. The incremental cost-effectiveness ratio was $121,924/life-years. Parameters which were most impactful (sensitivity analysis) included the median overall survival of patients with advanced disease treated with personalized therapy, cost of personalized therapy for advanced disease, and the probability of receiving personalized therapy in advanced disease. A strategy of selective testing was more cost-effective in 59% of iterations when the willingness-to-pay threshold was set to $100,000/life-years.

Conclusion: Our model suggested that selective germline testing of patients with newly diagnosed pancreatic cancer is more cost-effective than universal testing. Additional research is needed to explore the impact of cascade testing of relatives on cost-effectiveness.

Similar articles

Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P, Dowling EC, Ferrone CR, Hong TS, Schrag D, Fernandez-Del Castillo C, Ryan DP, Kong CY, Hur C.Oncologist. 2019 Jul;24(7):945-954. doi: 10.1634/theoncologist.2018-0114. Epub 2018 Dec 17.PMID: 30559125 Free PMC article.
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.
Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA.Ann Intern Med. 2011 Jul 19;155(2):69-79. doi: 10.7326/0003-4819-155-2-201107190-00002.PMID: 21768580 Free PMC article.
A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome.
Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C.Health Technol Assess. 2014 Sep;18(58):1-406. doi: 10.3310/hta18580.PMID: 25244061 Free PMC article. Review.
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.PMID: 17999840 Review.
The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome.
Kang YJ, Killen J, Caruana M, Simms K, Taylor N, Frayling IM, Snowsill T, Huxley N, Coupe VM, Hughes S, Freeman V, Boussioutas A, Trainer AH, Ward RL, Mitchell G, Macrae FA, Canfell K.Med J Aust. 2020 Feb;212(2):72-81. doi: 10.5694/mja2.50356. Epub 2019 Oct 8.PMID: 31595523 Free PMC article.